Suresh and colleagues reported a significant increase in CD4+ T cells in the BAL samples of CIP patients, primarily those with NSCLC, following treatment with anti-PD-1/PD-L1 inhibitors (57). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.